A. Khandhar, J. Erasmus, B. Berube, T. Kimura, M. Duthie, N. Warner, D. Hawman, P. Berglund, J. Reed, S. Reed
HDT bio, Washington, United States
Keywords: LION™ Nanoparticle, Replicon, Adjuvants, Gene-encoded therapeutics, Safety
HDT bio's proprietary LION™ platform provides "plug-and-play" capability to enable delivery of multiple payload types. First-generation LION is a clinical stage asset that is powering HDT's AMPLIFY™ and ACTIVATE™ technology pipelines. AMPLIFY™ leverages replicon RNA technology to deliver gene-encoded biological countermeasures with demonstrated preventive and therapeutic efficacy against a range of infectious diseases and toxins. The ACTIVATE™ pipeline comprises a toolbox of host-directed therapeutics that leverage the power of the innate immune system to provide pathogen-agnostic (broad spectrum) protection or enable immune reprogramming to either break tolerance against refractory tumors or induce tolerance in allergy and autoimmune disorders. First-gen LION™ enables rapid payload delivery to resident cells - in a matter of seconds - a key mechanism that underpins its enhanced safety profile for vaccine applications compared to LNPs. We have also developed a library family of over 300 derivatives of LION™ that unlock alternate routes of administration, from mucosal (intranasal and sublingual) to intravenous delivery, with precision targeting to select tissues (e.g. lungs and spleen). Lastly, HDT's LION-enabled products are supported by a partnering network providing AI/ML antigen and antibody discovery and end-to-end continuous manufacturing solutions.